Both the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) guidelines recommend that EGFR testing is essential in patients with metastatic non-squamous NSCLC.2 Here, EGFR is linked to non-small cell lung carcinoma.